Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.18898
Abstract: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. read more here.
Keywords: phase; baricitinib patients; topical corticosteroids; atopic dermatitis ... See more keywords